Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Nemtabrutinib plus venetoclax in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the dose escalation and confirmation segment of the Phase 3 bellwave-010 study

Paolo Ghia, Mauricio Chandia Cabas, Vernon Johan Louw, Maria Del Carmen Martinez Chamorro, Gonzalo Garate, Valeria Buccheri, Raimundo Gazitua Pepper, Alejandro Berkovits, Michael Cass, Eva Gonzalez Barca, Jose D. Sandoval-Sus, Muhit Ozcan, Sven Erik Ojavee, Ima Paydar, Mohammed Z.H. Farooqui, Ohad Benjamini

Blood (2025) 146 (Supplement 1): 2119.

https://doi.org/10.1182/blood-2025-2119

Published: 2025

Journal Articles

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Ana Marin Niebla, Eva Gine, Mariana Bastos-Oreiro, Amanda Perez, Alba Cabirta, Fatima De la Cruz Vicente, Marta Canelo Vilaseca, Ana Jiménez Ubieto, Sonia González De Villambrosia, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Pilar Gomez Prieto, Raul Cordoba, Ana Saus Carreres, Alejandro Martin Garcia-Sancho, Ana Maria Garcia-Noblejas Moya, Carlos Grande, Pablo Prieto Martínez, Concepción Nicolás, Antonio Gutierrez, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Maria Teresa Villalobos, Tomas García-Cerecedo, Rosalia Alonso Trillo, Eva Donato, Paola Villafuerte Gutiérrez, Daniel García Belmonte, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Juan-Manuel Sancho, Beatriz De La Cruz, Raja Prince-Eladnani, Pau Abrisqueta

Blood (2025) 146 (Supplement 1): 3592.

https://doi.org/10.1182/blood-2025-3592

Published: 2025

Journal Articles

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Mariana Bastos-Oreiro, Alba Cabirta, Amanda Perez, Ana Saus Carreres, Sonia González De Villambrosia, Marta Canelo, Ana Maria Garcia-Noblejas Moya, Beatriz De La Cruz Benito, Paola Villafuerte Gutiérrez, Fatima De la Cruz Vicente, Juan Carlos Caballero, Ana Jiménez-Ubieto, Daniel García Belmonte, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Alejandro Martin Garcia-Sancho, Carlos Grande, Concepción Nicolás, Antonio Gutierrez, Marina Gomez-Llobell, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Ainara Ferrero Campos, Rosalia Alonso Trillo, Eva Donato, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Pilar Gomez Prieto, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Raul Cordoba, Juan-Manuel Sancho, Eva Gine, Víctor Navarro Garces, Pau Abrisqueta, Ana Marin Niebla

Blood (2025) 146 (Supplement 1): 3585.

https://doi.org/10.1182/blood-2025-3585

Published: 2025

Journal Articles

Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial

Chan Cheah, Stephen Spurgeon, Sung-Soo Yoon, Melina Boutin, Eva Gonzalez Barca, Krimo Bouabdallah, Ellie John, Tatjana Krautloher, Victoria Otero, Brad Kahl

Blood (2025) 146 (Supplement 1): 3578.

https://doi.org/10.1182/blood-2025-3578

Published: 2025

Journal Articles

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Blood (2025) 146 (Supplement 1): 899.

https://doi.org/10.1182/blood-2025-899

Published: 2025

Journal Articles

Letermovir primary prophylaxis is associated with reduced and delayed CMV reactivation in haploidentical allohct using ptcy.

Felipe Peña-Muñoz, Fernando Molina, Marta Peña, Julia Ribes-Amoros, Anna Torrent, Maria Huguet, Merce Aren Jubany, Silvana Novelli, Cristina Fernandez, Raquel Lopez, Lidia Hurtado, Montserrat Arnan, Eva Gonzalez Barca, Carlota Gudiol, Julia Laporte, Anna Sureda Balarí, Alberto Mussetti

Blood (2025) 146 (Supplement 1): 7711.

https://doi.org/10.1182/blood-2025-7711

Published: 2025

Journal Articles

Epidemiology and clinical characteristics of idiopathic multicentric castleman disease in Spain (ARCANA study): Prevalence cohort

Jose Tomas Navarro, Ana Jiménez Ubieto, Araceli Rubio Martinez, Alejandro Martin Garcia-Sancho, Eva Gonzalez Barca, Pablo Lorente, Paloma Garcia Martin, Guillermo Rodríguez Garcia, Manuel Espeso De Haro, Antonio Gutierrez, Angel Ramirez, Inigo Olazabal Eizaguirre, Antonio Garcia, Xavier Cintas, Andres Gonzalez Garcia, Santiago Montes-Moreno

Blood (2025) 146 (Supplement 1): 3006.

https://doi.org/10.1182/blood-2025-3006

Published: 2025

Journal Articles

Castleman disease as a spectrum: Characterization of novel subtypes using data from the spanish GELTAMO registry

Blood (2025) 146 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2025-1233

Published: 2025

Journal Articles

Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group

Blood (2025) 146 (Supplement 1): 472.

https://doi.org/10.1182/blood-2025-472

Published: 2025

Journal Articles

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007

Marco Ladetto, David Lavie, Tae Min Kim, Eva Gonzalez Barca, Ewa Paszkiewicz-Kozik, Stefan Hohaus, Caterina Patti, Jan Zaucha, Ömür Gökmen Sevindik, Yulia Volchek, Raul Cordoba, Guillermo Rodríguez Garcia, Sebastian Giebel, Benedetta Puccini, Tadeusz Robak, Siruo Wang, Puja Patel, Rushdia Yusuf, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 5516.

https://doi.org/10.1182/blood-2025-5516

Published: 2025

Journal Articles

First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)

Blood (2025) 146 (Supplement 1): 3677.

https://doi.org/10.1182/blood-2025-3677

Published: 2025

Journal Articles

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Blood (2025) 146 (Supplement 1): 66.

https://doi.org/10.1182/blood-2025-66

Published: 2025

Journal Articles

Comorbid but transplantable: Favorable outcomes with RIC and ptcy in patients with an HCT-CI score of 3 or higher in the modern era

Alfredo De La Torre, Claudia Biosca, Felipe Peña-Muñoz, Marta Peña, Julia Ribes-Amoros, Anna Torrent, María Huguet, Merce Aren Jubany, Silvana Novelli, Cristina Fernandez, Raquel Lopez, Lidia Hurtado, Nicolás Real, Montserrat Arnan, Eva Gonzalez Barca, Anna Sureda Balarí, Alberto Mussetti

Blood (2025) 146 (Supplement 1): 2430.

https://doi.org/10.1182/blood-2025-2430

Published: 2025

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Blood (2024) 144 (Supplement 1): 4947.

https://doi.org/10.1182/blood-2024-202933

Published: 2024

Journal Articles

Predictive Value of Interim and End of Treatment PET/CT in Front-Line Treatment of Peripheral T-Cell Lymphoma

Nicolo Rampi, Belen Hervas Sanz, Carolina Esther Arevalo Leon, Angelo Castellani, Patricia Lopez Pereira, Elena Bechtold Javier, Ana C de Oliveira, Sara Pacella, Carmen Aguilera, Anna Valer, Eva Gonzalez Barca, Francesca Gaia Rossi, Carolina Martinez-Ramos, Ana Maria Sureda Balari, Montserrat Cortes-Romera, Eva Domingo Domenech

Blood (2024) 144 (Supplement 1): 6417.

https://doi.org/10.1182/blood-2024-210108

Published: 2024

Journal Articles

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Antonio Gutiérrez, Izaskun Zeberio, Pilar Martinez-Barranco, Francisco Javier Peñalver, Sandra Pérez, Daniel Morillo, Xabier Mart N Martitegui, Concepción Nicolás, Ainara Ferrero, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Julio Dávila-Valls, Maria Victoria Calle Gordo, María Pérez Sala, Guillermo Rodríguez Garcia, Aranzazu Alonso Alonso, Ana Garcia Noblejas, Diana Sanchez Arguello, Teresa Knight Asorey, Maria Angeles Fernandez Fernandez, Javier López Marin, Jaime Perez de Oteyza, Sonia González De Villambrosia, Elena Perez Ceballos, Alejandro Marin, Belén Navarro, Ruben Fernandez Alvarez, Pilar Gómez, Jose Antonio Hueso, Maria Jesus Penarrubia Ponce, Pilar Bravo, Daniel García Belmonte, Haridian De La Nuez Melian, Sara Nistal, Pau Abrisqueta Costa, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio Rincon, Maria Stefania Infante, Eva Gonzalez Barca

Blood (2024) 144 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2024-210868

Published: 2024

Journal Articles

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 578.

https://doi.org/10.1182/blood-2024-200271

Published: 2024

Journal Articles

Pre-Transplant Diabetes Is Associated with Increased Risk of Relapse after HCT: A Single Center Experience

Annalisa Paviglianiti, Marta Bellver Sanchis, Marta Peña, Inmaculada Peiro Martinez, Felipe Peña, Lidia Hurtado, Raquel Lopez Gil, Alberto Mussetti, Montserrat Arnan, Helena Pomares, Eva Gonzalez Barca, Patricia Lopez Pereira, Rocky Strollo, Paolo Pozzilli, Anna Sureda Balari

Blood (2024) 144 (Supplement 1): 7412.

https://doi.org/10.1182/blood-2024-198124

Published: 2024

Journal Articles

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Xavier C. Badoux, Jacqueline C. Barrientos, Alessandra Tedeschi, Stephen Opat, Ian W. Flinn, Eva Gonzalez Barca, Ryan Jacobs, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, William G. Wierda, Paolo Ghia, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 224–227.

https://doi.org/10.1182/blood-2022-160338

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Nemtabrutinib plus venetoclax in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the dose escalation and confirmation segment of the Phase 3 bellwave-010 study

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Letermovir primary prophylaxis is associated with reduced and delayed CMV reactivation in haploidentical allohct using ptcy.

Epidemiology and clinical characteristics of idiopathic multicentric castleman disease in Spain (ARCANA study): Prevalence cohort

Castleman disease as a spectrum: Characterization of novel subtypes using data from the spanish GELTAMO registry

Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007

First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Comorbid but transplantable: Favorable outcomes with RIC and ptcy in patients with an HCT-CI score of 3 or higher in the modern era

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Predictive Value of Interim and End of Treatment PET/CT in Front-Line Treatment of Peripheral T-Cell Lymphoma

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Pre-Transplant Diabetes Is Associated with Increased Risk of Relapse after HCT: A Single Center Experience

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only